ADCYAP1 and migraine disorder: While PACAP poses an exciting therapeutic avenue in migraine and cluster headache, thus far we only have a failed phase 2 trial of a PAC1 receptor antibody and an encouraging phase 2 trial of a ligand PACAP antibody with results available.